”Yunque” treatment of rheumatoid arthritis, not only has the anti-inflammatory and analgesic effect of non-somatic anti-inflammatory drugs, but also has the immunosuppressive effect of hormones and slow-acting anti-rheumatic drugs, that is, it has the effect of both the symptoms and the root cause, and does not have the serious toxic side effects of conventional anti-rheumatic drugs. Compared with conventional anti-rheumatic drugs, “Yunque” treatment of RA fast onset of action (generally 10 to 20 injections can be effective, a few patients to 30-40. 1, what is rheumatoid arthritis? Rheumatoid arthritis (RA) is a chronic, recurrent, non-specific and multiple arthritis, it is a local manifestation of the systemic connective tissue and collagen fibrous tissue lesions, especially in the hands of fingers, toes and other small joints are most susceptible to early or acute onset, joint redness, swelling, heat, pain and movement disorders, the late stage is joint ankylosis or deformity, and bone and skeletal muscle atrophy. Throughout the course of the disease, there is fever, malaise, anemia, and multiple morbidity. The incidence is higher in women than in men, with a male to female ratio of 1:3 and an overall incidence of about 0.4%. The etiology of the disease is unclear, and it is generally believed that its onset is related to autoimmunity, genetics, infection, viruses, and endocrine changes. The disease has a high rate of disability, untreated patients, two-year disability rate of 50%, three-year disability rate of 70%, compared with normal people, rheumatoid arthritis patients shorten the average life expectancy of 10-15 years, so the disease should be diagnosed and treated early to avoid disability or reduce the disability rate. 2.How to diagnose rheumatoid arthritis? According to the American Rheumatism Association (ARA) 1987 diagnostic criteria, rheumatoid arthritis can be diagnosed with four or more of the following criteria: (1) morning stiffness lasting more than 1 hour (>6 weeks); (2) swelling of more than 3 joints (>6 weeks); (3) swelling of the wrist, palm, finger and proximal interphalangeal joints (>6 weeks); (4) symmetrical joint inflammation (>6 weeks); (5) consistent with X-ray changes in the hand typical of rheumatoid arthritis and must include bone erosive lesions or definite bone decalcification; (6) rheumatoid nodules; (7) positive serum rheumatoid factor (titer above the highest normal value). Among them, rheumatoid factor is not a specific indicator, rheumatoid factor positive is not necessarily rheumatoid arthritis, in recent years found that certain more specific diagnostic indicators, such as antiperinuclear factor (APF), anti-keratin antibody (AKA), anti-CCP antibody, etc. have a higher sensitivity and specificity for the diagnosis of RA. 3.What are the characteristics of “Yunque” for rheumatoid arthritis, and what are the fundamental differences between “Yunque” and conventional anti-rheumatic drugs? ”Yunque” treatment of rheumatoid arthritis, not only has the anti-inflammatory and analgesic effect of non-body anti-inflammatory drugs, but also has the immunosuppressive effect of hormones and slow-acting anti-rheumatic drugs, that is, it has the effect of both primary and secondary treatment, and does not have the serious toxic side effects of conventional anti-rheumatic drugs. Compared with the conventional anti-rheumatic drugs, “Yunke” treatment of RA fast onset of action (generally 10 to 20 needles can be effective, a few patients need 30-40 needles to take effect), high efficiency, a course of treatment (20 needles), the efficiency of more than 80%, two courses of treatment (40 needles), the efficiency of up to 90%, and with conventional anti-rheumatic drugs need to maintain a certain blood concentration to maintain the efficacy of the disease will be discontinued and Unlike conventional anti-rheumatic drugs that need to maintain a certain blood concentration to maintain the effect, and the disease will be repeatedly aggravated after stopping, “Yunque” has a long metabolic period in the body (generally 1-10 years), “Yunque” will work in the human body for a long time, so the long-term efficacy is good, and there are patients who have been treated for the latter 7 years without relapse and aggravation of the disease. Conventional anti-rheumatic drugs cannot control the development and deterioration of RA patients, let alone reversing the disease of RA patients, repairing the damaged joints, or making them lose their active functions. ”The essential difference between “Yunque” and conventional anti-rheumatic drugs is that “Yunque” can not only control the development of RA patients’ disease (such as making inflammatory synovitis decompensated, improving and maintaining joint function, preventing osteoporosis of bone and joint ends, and restoring joint activity function, that is, it can reverse the disease of RA patients. The fact that the function of joint movement has been significantly improved or restored, and that they can get out of bed and resume the ability to take care of themselves is a strong proof. Apart from rheumatoid arthritis, what other autoimmune bone and joint diseases can be treated with “Yunque”? ”Yunque” mainly treats rheumatoid arthritis, because “Yunque” has good anti-inflammatory and analgesic effects, and can regulate human immune function, so in addition to treating rheumatoid arthritis, it can also treat some other autoimmune diseases. Clinical trials have initially proved that “Yunque” is also good for treating ankylosing columnitis, psoriatic arthritis, Paget’s disease, systemic lupus erythematosus and other autoimmune diseases.